Fatigue, depression, and product tolerability during long-term treatment with intravenous immunoglobulin (Gamunex® 10%) in patients with chronic inflammatory demyelinating polyneuropathy

Peer Review reports

Original Submission
20 Sep 2022	Submitted	Original manuscript
Resubmission - Version 2
	Submitted	Manuscript version 2
13 Nov 2022	Reviewed	Reviewer Report
28 Nov 2022	Reviewed	Reviewer Report
1 Mar 2023	Author responded	Author comments - Bernd C. Kieseier
Resubmission - Version 3
1 Mar 2023	Submitted	Manuscript version 3
5 Mar 2023	Reviewed	Reviewer Report
21 Apr 2023	Reviewed	Reviewer Report
Resubmission - Version 4
	Submitted	Manuscript version 4
Publishing
22 Apr 2023	Editorially accepted
26 May 2023	Article published	10.1186/s12883-023-03223-5

Back to article page